References

  1. 1.Virani SS, Alonso A, Benjamin EJ, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596.
  2. 2.Unkart JT, Allison MA, Araneta MRG, et al. Burden of peripheral artery disease on mortality and incident cardiovascular events. Am J Epidemiol. 2020;189(9):951-962.
  3. 3.Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313-e1410.
  4. 4.Nordanstig J, Behrendt CA, Baumgartner I, et al. Editor’s choice — European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication. Eur J Vasc Endovasc Surg. 2024;67(1):9-96.
  5. 5.Curry SJ, Krist AH, Owens DK, et al.; US Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(2):177-183.
  6. 6.Guirguis-Blake JM, Evans CV, Redmond N, et al. Screening for peripheral artery disease using the ankle-brachial index: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(2):184-196.
  7. 7.Polonsky TS, McDermott MM. Lower extremity peripheral artery disease without chronic limb-threatening ischemia: a review. JAMA. 2021;325(21):2188-2198.
  8. 8.McDermott MM. Exercise rehabilitation for peripheral artery disease: a review. J Cardiopulm Rehabil Prev. 2018;38(2):63-69.
  9. 9.Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909-1919.
  10. 10.CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
  11. 11.Hiatt WR, Fowkes FGR, Heizer G, et al.; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32-40.
  12. 12.Cacoub PP, Bhatt DL, Steg PG, et al.; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2):192-201.
  13. 13.Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330.
  14. 14.Fowkes FGR, Price JF, Stewart MCW, et al.; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841-848.
  15. 15.Arya S, Khakharia A, Binney ZO, et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation. 2018;137(14):1435-1446.
  16. 16.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.
  17. 17.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.
  18. 18.Sleight P. The HOPE study (heart outcomes prevention evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1(1):18-20.
  19. 19.Armstrong EJ, Chen DC, Singh GD, et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med. 2015;20(3):237-244.
  20. 20.Verma S, Al-Omran M, Leiter LA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24(7):1288-1299.
  21. 21.Brown T, Forster RB, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021(6):CD003748.
  22. 22.Beckman JA, Schneider PA, Conte MS. Advances in revascularization for peripheral artery disease: revascularization in PAD. Circ Res. 2021;128(12):1885-1912.
  1. 1.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
  2. 2.Pencina MJ, D’Agostino RB. Evaluating discrimination of risk prediction models: the C statistic. JAMA. 2015;314(10):1063-1064.
  3. 3.Medina-Inojosa JR, Somers VK, Garcia M, et al. Performance of the ACC/AHA pooled cohort cardiovascular risk equations in clinical practice. J Am Coll Cardiol. 2023;82(15):1499-1508.
  4. 4.Khan SS, Matsushita K, Sang Y, et al.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449.
  5. 5.McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66(15):1643-1653.
  6. 6.Parsons RE, Liu X, Collister JA, et al. Independent external validation of the QRISK3 cardiovascular disease risk prediction model using UK Biobank. Heart. 2023;109(22):1690-1697.
  7. 7.Carson AP, Chang AR, Ciemins E, et al.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449.
  8. 8.Kamstrup PR, Neely RDG, Nissen S, et al. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research. Eur J Prev Cardiol. 2024;31(7):903-914.
  9. 9.Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392.
  10. 10.Rehberger Likozar A, Zavrtanik M, šebeštjen M. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Ann Med. 2020;52(5):162-177.
  11. 11.Paré G, Çaku A, McQueen M, et al. INTERHEART Investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472-1482.
  12. 12.Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol. 2022;79(8):757-768.
  13. 13.Contois JH, Langlois MR, Cobbaert C, et al. Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol. J Am Heart Assoc. 2023;12(15):e030405.
  14. 14.De Oliveira-Gomes D, Joshi PH, Peterson ED, et al. Apolipoprotein B: bridging the gap between evidence and clinical practice. Circulation. 2024;150(1):62-79.
  15. 15.Glavinovic T, Thanassoulis G, de Graaf J, et al. Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk. J Am Heart Assoc. 2022;11(20):e025858.
  16. 16.Johannesen CDL, Mortensen MB, Langsted A, et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439-1450.
  17. 17.Carr SS, Hooper AJ, Sullivan DR, et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-154.
  18. 18.Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.
  19. 19.Lin JS, Evans CV, Johnson E, et al. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(3):281-297.
  20. 20.Khan SS, Post WS, Guo X, et al. Coronary artery calcium score and polygenic risk score for the prediction of coronary heart disease events. JAMA. 2023;329(20):1768-1777.
  21. 21.Blaha MJ, DeFilippis AP. Multi-Ethnic Study of Atherosclerosis (MESA): JACC focus seminar 5/8. J Am Coll Cardiol. 2021;77(25):3195-3216.
  22. 22.Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378(9792):684-692.
  23. 23.Jonas DE, Reddy S, Middleton JC, et al. Screening for cardiovascular disease risk with resting or exercise electrocardiography: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(22):2315-2328.
  24. 24.Newby DE, Adamson PD, Berry C, et al.; SCOT-HEART Investigators. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924-933.
  25. 25.Neglia D, Rovai D, Caselli C, et al.; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015;8(3):e002179.
  26. 26.Foy AJ, Dhruva SS, Peterson B, et al. Coronary computed tomography angiography vs functional stress testing for patients with suspected coronary artery disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(11):1623-1631.
  27. 27.Zito A, Galli M, Biondi-Zoccai G, et al. Diagnostic strategies for the assessment of suspected stable coronary artery disease: a systematic review and meta-analysis. Ann Intern Med. 2023;176(6):817-826.
  28. 28.Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336-1345.
  29. 29.Choi HYJ. Coronary artery calcium scoring for prevention of cardiovascular disease. Am Fam Physician. 2022;106(1):93-94.
  30. 30.Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
  31. 31.Davidson KW, Barry MJ, Mangione CM, et al.; US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577-1584.
  1. 1.Vrints C, Andreotti F, Koskinas KC, et al.; ESC Scientific Document Group. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537.
  2. 2.Virani SS, Newby LK, Arnold SV, et al.; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119.
  3. 3.Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics–2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153-e639.
  4. 4.Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):241.
  5. 5.Rees K, Takeda A, Martin N, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2019(3):CD009825.
  6. 6.de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785.
  7. 7.Hooper L, Martin N, Jimoh OF, et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020(5):CD011737.
  8. 8.Medina-Inojosa JR, Grace SL, Supervia M, et al. Dose of cardiac rehabilitation to reduce mortality and morbidity: a population-based study. J Am Heart Assoc. 2021;10(20):e021356.
  9. 9.Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2021(11):CD001800.
  10. 10.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.
  11. 11.Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
  12. 12.Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(9):959-966.
  13. 13.Bhatt DL, Steg PG, Miller M, et al.; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.
  14. 14.Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER Trial. JAMA Cardiol. 2019;4(7):613-619.
  15. 15.Nissen SE, Lincoff AM, Brennan D, et al.; CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-in-tolerant patients. N Engl J Med. 2023;388(15):1353-1364.
  16. 16.Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780-1788.
  17. 17.Ray KK, Raal FJ, Kallend DG, et al.; ORION Phase III Investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129-138.
  18. 18.Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2022(11):CD010315.
  19. 19.American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(1 suppl 1):S128-S145.
  20. 20.American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 suppl 1):S207-S238.
  21. 21.Xu D, Nair A, Sigston C, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations. Cardiovascular Therapeutics. 2022. https://onlinelibrary.wiley.com/doi/10.1155/2022/6820377
  22. 22.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
  23. 23.Sorbets E, Steg PG, Young R, et al.; CLARIFY Investigators. B-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399-1407.
  24. 24.Davies A, Fox K, Galassi AR, et al. Management of refractory angina: an update. Eur Heart J. 2021;42(3):269-283.
  25. 25.Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a ‘diamond’ approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120-132.
  26. 26.Steg PG, Greenlaw N, Tendera M, et al.; Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med. 2014;174(10):1651-1659.
  27. 27.Ford TJ, Redwood E, Chuah E. Coronary sinus reduction: can device-based therapy improve coronary microvascular function? Circ Cardiovasc Interv. 2024;17(1):e013831.
  28. 28.Verheye S, Jolicoeur EM, Behan MW, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015;372(6):519-527.
  29. 29.Gragnano F, Cao D, Pirondini L, et al.; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82(2):89-105.
  30. 30.Bonaca MP, Bhatt DL, Cohen M, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-1800.
  31. 31.Cho MS, Kang DY, Ahn JM, et al.; EPIC-CAD Investigators. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024;391(22):2075-2086.
  32. 32.Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Front Pharmacol. 2021;12:694-698.
  33. 33.Sorbets E, Fox KM, Elbez Y, et al.; CLARIFY Investigators. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2020;41(3):347-356.
  34. 34.Smulders MW, Jaarsma C, Nelemans PJ, et al. Comparison of the prognostic value of negative non-invasive cardiac investigations in patients with suspected or known coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2017;18(9):980-987.
  35. 35.Roger VL. Medicine and society: social determinants of health and cardiovascular disease. Eur Heart J. 2020;41(11):1179-1181.
  36. 36.Berman AN, Biery DW, Ginder C, et al. Association of socioeconomic disadvantage with long-term mortality after myocardial infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol. 2021;6(8):880-888.
  37. 37.Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation. 2018;137(20):2166-2178.
  38. 38.Kim K, Choi JS, Choi E, et al. Effects of community-based health worker interventions to improve chronic disease management and care among vulnerable populations: a systematic review. Am J Public Health. 2016;106(4):e3-e28.
  1. 1.Bozkurt B, Ahmad T, Alexander KM, et al.; Writing Committee Members. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412-1451.
  2. 2.Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421.
  3. 3.Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61-73.
  4. 4.Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981;64(6):1227-1234.
  5. 5.Bozkurt B. How to initiate and uptitrate GDMT in heart failure: practical stepwise approach to optimization of GDMT. JACC Heart Fail. 2022;10(12):992-995.
  6. 6.Yancy CW, Jessup M, Bozkurt B, et al.; Writing Committee Members; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-e327.
  7. 7.Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861-870.
  8. 8.Booth RA, Hill SA, Don-Wauchope A, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev. 2014;19(4):439-451.
  9. 9.Meijers WC, van der Velde AR, de Boer RA. Biomarkers in heart failure with preserved ejection fraction. Neth Heart J. 2016;24(4):252-258.
  10. 10.Donal E, Lund LH, Oger E, et al.; KaRen investigators. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging. 2016;17(1):106-113.
  11. 11.Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588-595.
  12. 12.Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023;25(7):936-955.
  13. 13.He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002.
  14. 14.Chow BJW, Coyle D, Hossain A, et al.; IMAGE-HF Investigators. Computed tomography coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE-HF 1C). Eur Heart J Cardiovasc Imaging. 2021;22(9):1083-1090.
  15. 15.Ferreira JP, Rossignol P, Demissei B, et al. Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart. 2018;104(7):606-613.
  16. 16.Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-3176.
  17. 17.Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964-1975.
  18. 18.Mentz RJ, Anstrom KJ, Eisenstein EL, et al.; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214-223.
  19. 19.Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(10):1178-1195.
  20. 20.Faselis C, Arundel C, Patel S, et al. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J Am Coll Cardiol. 2020;76(6):669-679.
  21. 21.Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-day readmission rates for heart failure. Circ Heart Fail. 2021;14(4):e008335.
  22. 22.Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938-1952.
  23. 23.Maddox TM, Januzzi JL, Allen LA, et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444-1488.
  24. 24.Greene SJ, Butler J, Fonarow GC. Rapid and intensive guideline-directed medical therapy for heart failure: 5 core principles. Circulation. 2024;150(6):422-424.
  25. 25.Greene SJ, Ayodele I, Pierce JB, et al. Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure. JACC Heart Fail. 2024;12(8):1365-1377.
  26. 26.Packer M, Poole-Wilson PA, Armstrong PW, et al.; ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100(23):2312-2318.
  27. 27.Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
  28. 28.Velazquez EJ, Morrow DA, DeVore AD, et al.; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539-548.
  29. 29.Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591-603.
  30. 30.Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
  31. 31.Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
  32. 32.Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829.
  33. 33.Swedberg K, Komajda M, Böhm M, et al.; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-885.
  34. 34.Borer JS, Böhm M, Ford I, et al.; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813-2820.
  35. 35.Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237.
  36. 36.Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883.
  37. 37.Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835-1878.
  38. 38.Solomon SD, McMurray JJV, Vaduganathan M, et al.; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485.
  39. 39.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.
  40. 40.Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084.
  41. 41.Packer M, Zile MR, Kramer CM, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437.
  42. 42.Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021;144(11):845-858.
  43. 43.Joglar JA, Chung MK, Armbruster AL, et al.; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
  44. 44.Granger CB, Alexander JH, McMurray JJV, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
  45. 45.Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10(6):e019636.
  46. 46.Ahmed MB, Patel K, Fonarow GC, et al. Higher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination. ESC Heart Fail. 2016;3(1):11-17.
  47. 47.Parenica J, Benesova K, Radvan M, et al. COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: a population-based study. Front Cardiovasc Med. 2022;9:998842.
  48. 48.Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced salt intake for heart failure: a systematic review. JAMA Intern Med. 2018;178(12):1693-1700.
  49. 49.Doukky R, Avery E, Mangla A, et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 2016;4(1):24-35.
  50. 50.Philipson H, Ekman I, Forslund HB, et al. Salt and fluid restriction is effective in patients with chronic heart failure. Eur J Heart Fail. 2013;15(11):1304-1310.
  51. 51.O’Connor CM, Whellan DJ, Lee KL, et al.; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-1450.
  52. 52.Fukuta H, Goto T, Wakami K, et al. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2019;24(4):535-547.
  53. 53.Kitzman DW, Whellan DJ, Duncan P, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021;385(3):203-216.
  54. 54.Freedland KE, Carney RM, Rich MW, et al. Depression and multiple rehospitalizations in patients with heart failure. Clin Cardiol. 2016;39(5):257-262.
  55. 55.Freedland KE, Hesseler MJ, Carney RM, et al. Major depression and long-term survival of patients with heart failure. Psychosom Med. 2016;78(8):896-903.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.